Dr. Choueiri on the Biology of the CABOSUN Trial for RCC

Toni K. Choueiri, MD
Published: Monday, Aug 21, 2017



Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the findings of the CABOSUN trial for patients with metastatic renal cell carcinoma (mRCC).

The CABOSUN trial investigated cabozantinib (Cabometyx) versus sunitinib (Sutent) in patients with mRCC.

According to Choueiri, it is interesting to see that something that makes sense biologically was able translate to clinical outcomes. Cabozantinib appeared to be superior to sunitinib, which is what was seen in the results of the study, explains Choueiri.
 


Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the findings of the CABOSUN trial for patients with metastatic renal cell carcinoma (mRCC).

The CABOSUN trial investigated cabozantinib (Cabometyx) versus sunitinib (Sutent) in patients with mRCC.

According to Choueiri, it is interesting to see that something that makes sense biologically was able translate to clinical outcomes. Cabozantinib appeared to be superior to sunitinib, which is what was seen in the results of the study, explains Choueiri.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x